ClinicalTrials.gg
RecruitingNCT07252765STARLIGHTUpdated Jan 28, 2026

Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice

An observational study in Type 2 Diabetes Mellitus (T2DM), Malnutrition and Malnourishment, sponsored by Outcomes'10. Recruiting at 12 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Outcomes'10 · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
334
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain — 44 open to participants now, 55 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · Spain.

Planned enrollment
29th of 46
334 · median 842
Started
2025
with 17 others
Observational
46 of 429
9 open now
Primary completion
2026-10
later than 16 of 54 live
Registered
401st of 429
by date

Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, this one is the 29th largest by planned enrollment of the 46 observational ones that give a count, is one of 18 that started in 2025, is one of 46 observational ones, reaches primary completion later than 16 of the 54 other live ones, and was the 401st registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

44 of the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, or all of them as a file.
02

Study summary

The objective of this observational study is to characterize the patient profile and nutritional treatment patterns of individuals with type 2 diabetes (T2D) or drug-induced diabetes who present with malnutrition, or are at risk of it, and who are prescribed a diabetes-specific oral nutritional supplement (ONS) that is high in calories and protein and contains soluble fiber.

Participants will complete a series of questionnaires during visits 1 and 3.

Read the detailed description
  1. Background and Rationale This study focuses on patients with type 2 diabetes mellitus (T2D) who also present with malnutrition or are at risk of developing malnutrition. These conditions negatively affect clinical and functional outcomes, increasing the likelihood of complications and hospitalizations. The use of diabetes-specific oral nutritional supplements (ONS)-characterized by a high caloric and protein content and enriched with soluble fiber-may contribute to improving clinical status, nutritional parameters, and quality of life. Nevertheless, current evidence from real-world clinical practice remains limited and heterogeneous.
  2. Primary Objective To characterize the clinical and nutritional profile, as well as the nutritional treatment patterns, of patients with T2D and malnutrition or at risk of malnutrition who are prescribed a diabetes-specific ONS.
  3. Secondary Objectives

    To assess changes in glycemic and metabolic control.

    To evaluate the nutritional and functional impact of the ONS.

    To analyze healthcare resource utilization and associated costs.

    To estimate patient adherence, compliance, and satisfaction with the prescribed ONS.

    To assess quality-of-life outcomes over a 6-month follow-up period.

  4. Exploratory Objective To explore changes in muscle mass using nutritional ultrasound.
  5. Study Design

    Multicenter, prospective, real-world evidence (RWE) study.

    Conducted across 12 hospitals in Spain.

    Three scheduled visits: baseline (V1), 3-month follow-up (V2), and 6-month final visit (V3).

  6. Study Population A total of 334 adult patients with T2D and either nutritional risk or malnutrition, all of whom are prescribed a diabetes-specific ONS.
  7. Collected Variables

    Sociodemographic: age, sex, education level, etc.

    Clinical and anthropometric: weight, muscle mass, comorbidities.

    ONS-related: product name, dosage, duration, modifications, palatability.

    Nutritional requirements: daily caloric, protein, fat, and carbohydrate needs.

    Healthcare resource utilization: hospital admissions, emergency visits, specialist consultations, and diabetes medication adjustments.

    Metabolic profile: HbA1c, fasting glucose, lipid panel, albumin, total protein, hemoglobin, liver enzymes, eGFR, and CRP.

    Functional assessment: SARC-F scale, handgrip strength, bioelectrical impedance analysis (BIA), nutritional ultrasound, and Timed Up and Go test.

    Patient-reported outcomes: NutriQoL® quality-of-life questionnaire, satisfaction survey, treatment adherence questionnaire, and ONS palatability scale.

  8. Data Management and Analysis Data will be managed by Outcomes'10 and analyzed using STATA v.14. Descriptive and comparative analyses will be conducted to address the primary and secondary objectives. All data will be reviewed and pseudonymized to ensure patient confidentiality.
03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
  • Malnutrition
  • Malnourishment
  • Drug-Induced Diabetes

Keywords

  • Metabolic control
  • Disease - realted malnutrition
  • Diabetes-specific formula
  • T2D
  • Oral nutritional supplementation
  • Type 2 Diabetes Mellitus
  • Malnourishment
  • Malnutrition
  • Drug-induced diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with type 2 diabetes (T2D) or drug-induced diabetes, at nutritional risk according to MUST and/or presenting malnutrition according to GLIM criteria, who require a diabetes-specific oral nutritional supplement (ONS) that is high-calorie, high-protein, and contains soluble fiber, and who have been prescribed such an ONS in real-world clinical practice within the previous 7 days

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients diagnosed with type 2 diabetes (T2D) or drug-induced diabetes
  • Patients at nutritional risk according to MUST or presenting malnutrition according to GLIM criteria.
  • Patients requiring a diabetes-specific oral nutritional supplement (ONS) that is high-calorie, high-protein, and contains soluble fiber in real-world clinical practice, and who have been prescribed such a supplement within the previous 7 days.
  • Patients able to provide and complete the study questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Patients participating in other studies or clinical trials related to malnutrition, or who, in the investigator's opinion, may alter the course of the study.
  • Patients currently receiving or expected to receive other types of nutritional interventions involving supplements (oral or otherwise) or non-conventional feeding methods (e.g., feeding tubes).
  • Patients with a history of metabolic/endocrine diseases (other than diabetes) or any other condition causing liver or kidney failure, defined as > 3x or \< 30 ml/min/1.73 m², and according to the investigator's judgment.
  • Patients expected to undergo any surgical intervention or require hospitalization due to a condition unrelated to the study during the study period.
  • Patients with other conditions that, in the investigator's opinion, may interfere with adherence to the intervention or with study procedures.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
334 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with T2D or with drug-induced diabetes and malnutrition or at risk of it
06

What researchers measure

Primary outcomes

  1. Descriptive of study population

    Descriptive information of the population at V1

    Time frame: Baseline visit (V1)

Secondary outcomes

  1. Percentage change of blood test parameters

    Changes in blood test measures will be compared

    Time frame: From enrollment to end of treatment at 24 weeks

  2. Percentage of patients with improvement in the nutritional status

    Changes in GLIM or MUST classifications

    Time frame: From enrollment to end of treatment at 24 weeks

  3. Associated cost at 6-month follow-up

    They will be estimated by multiplying the number of units used by their unit cost (derived from eSalud and Botplus databases). Unit: Number of events; euros (€)

    Time frame: From enrollment to end of treatment at 24 weeks

  4. Adherence with prescribed oral nutritional supplement (ONS)

    Participants will be categorized as compliant (≥80% consumption) or non-compliant (\<80%).

    Time frame: From enrollment to end of treatment at 24 weeks

  5. Change in functional status of participants over time

    Changes between visits in SARC-F scale categories

    Time frame: From enrollment to end of treatment at 24 weeks

  6. Change in NutriQoL® quality-of-life score

    Patients will be classified according to a quality-of-life category (excellent, good, acceptable, poor, very poor). Test total scoring values.

    Time frame: From enrollment to end of treatment at 24 weeks

  7. Patient satisfaction of the ONS product at 6 months

    Responses to the satisfaction questionnaires will be summarized as number and percentage of participants selecting each category at V3.

    Time frame: From enrollment to end of treatment at 24 weeks

  8. Patient palatability of the ONS product at 6 months

    Responses to the palatability questionnaires will be summarized as number and percentage of participants selecting each category at V3.

    Time frame: From enrollment to end of treatment at 24 weeks

  9. Health resource use

    Frequencies of treatment changes, administration route, specialist consultations, and hospitalizations will be recorded and quantitative variables (treatment dose, treatment duration, number and days of hospitalization, consultations) will be summarized using mean ± SD.

    Time frame: From enrollment to end of treatment at 24 weeks

  10. Change in nutritional status

    It will be estimated according to GLIM or MUST classification

    Time frame: From enrollment to end of treatment at 24 weeks

  11. Percentage change in BMI

    Weight and height will be combined to report BMI in kg/m2

    Time frame: From enrollment to end of treatment at 24 weeks

  12. Maximum prehensile strenght value

    Probe: handgrip test by using a hand dynamometer

    Time frame: From enrollment to end of treatment at 24 weeks

  13. 30" chair test

    Test: a patient will have to stand-up and sit-down as maximim number of times in 30", from a chair, with both arms crossed in the chest.

    Time frame: From enrollment to end of treatment at 24 weeks

  14. Impedancimetry values

    Test: bioimpedance

    Time frame: From enrollment to end of treatment at 24 weeks

Other outcomes

  1. Nutritional status at molecular level

    Test: nutritional (morphofunctional) ecography

    Time frame: From enrollment to end of treatment at 24 weeks

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Oct 2026, 11 months after the start.

Of 436 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 11 months is below that.

Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Nov 28, 2025
StartActual
Nov 20, 2025
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07252765
Lead sponsor
Outcomes'10
Collaborators
Nestlé Health Science Spain
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Nov 20, 2025
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Jan 28, 2026

Study contacts

Mercedes Blanco Naveira, Medical Adviser. MD
Contact
mercedes.blanco@es.nestle.com
+34 628 237 634

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion